Given the mechanistic overlap between T2DM and AD, it is logical to pursue anti-diabetic medications to treat AD and their effects are likely to be synergistic with other classes of medications such as cholinesterase inhibitors and anti-amyloid monoclonal antibodies. The gene discussed is BCHE; the disease is Alzheimer disease.